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ABSTRACT 1 
Background: Infrequent intra-procedural premature ventricular complexes (PVCs) may impede 2 
radiofrequency catheter ablation (RFA) outcome and pharmacological induction is 3 
unpredictable.  4 
Objective: To determine whether PVC circadian variation could help predict drug response. 5 
Methods: Consecutive patients referred for RFA with detailed Holter monitoring and frequent 6 
monomorphic PVCs were included. Patients were divided into 3 groups based on hourly PVC 7 
count relationship to corresponding mean HR during each of the 24 hours on Holter: fast-HR-8 
dependent PVC (F-HR-PVC) type for a positive correlation (Pearson, P<0.05), slow-HR-9 
dependent PVC (S-HR-PVC) type for a negative one and independent-HR-PVC (I-HR-PVC) 10 
when no correlation was found. 11 
Results: Fifty one of the 101 pts (50.5%) had F-HR-PVC, 39.6% I-HR-PVC and 9.9% S-HR-12 
PVC. 30.7% of pts had infrequent intra-procedural PVC requiring drug infusion. The best 13 
predictor of infrequent PVC was number of hours with a PVC count<120/h on Holter 14 
(AUC=0.80, Se=83.9%, Spe=74.3%, for ≥2h). Only F-HR-PVC pts responded to isoproterenol. 15 
Isoproterenol washout or phenylephrine infusion were successful for the 3 S-HR-PVC pts; and 16 
no drug could increase PVC frequency in the 12 I-HR-PVC pts. Long term RFA success rate in 17 
pts with frequent PVCs at baseline (82.9%) was similar to those with infrequent PVC who 18 
responded to a drug (77.8%, P=0.732), but significantly higher than for those who did not 19 
respond to any drug (15.4%, P<0.0001). 20 
Conclusion: A simple analysis of Holter PVC circadian variability provides incremental value to 21 
guide pharmacologic induction of PVCs during RFA and predict outcome. Patients with 22 
infrequent I-HR-PVC had the least successful outcomes from RF ablation.  23 
 24 
Key words: premature ventricular complexes, radiofrequency ablation, circadian, isoproterenol, 25 
autonomic nervous system. 26 
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 1 
INTRODUCTION 2 
Premature ventricular contractions (PVCs) are frequently encountered in clinical practice and 3 
may cause symptoms, lead to cardiomyopathy,1, 2 or even cause sudden cardiac death.3, 4 4 
Radiofrequency ablation (RFA) of PVCs is routinely performed, aiming to prevent these risks 5 
and manage drug-refractory symptoms.5  6 
 7 
However, infrequent intra-procedural PVCs makes activation mapping difficult, impeding the 8 
ablation procedure and resulting in reduced short and long- term ablation success rates.6 Pace-9 
mapping is of limited value as an alternative approach. Isoproterenol, sometimes in combination 10 
with pacing maneuvers, is used in such instances to increase intra-procedural PVC frequency. 11 
Successful induction of PVCs with isoproterenol has been reported in less than 50% of cases,6 12 
and no specific criteria have been developed to predict the likelihood of success. In addition to 13 
its unreliability in enhancing PVC frequency, isoproterenol is also a very expensive drug in the 14 
United States (~$1200/dose); and may in rare instances lead to serious complications.7, 8 15 
 16 
Idiopathic PVCs are thought to be mainly sympathetically-mediated, making the utilization of 17 
isoproterenol to increase intra-procedure PVC burden a rational strategy. However, the 18 
circadian distribution of PVCs is highly variable between patients suggesting a more complex 19 
autonomic neural control. A subset of patients seems to have a preferentially higher burden 20 
during daytime and as heart rate (HR) accelerates (e.g., exercise, stress), while PVCs are 21 
suppressed at night or rest. However, some patients have the opposite distribution pattern, 22 
where PVCs are mainly present at night/rest, but infrequent during the day/activity. A third group 23 
of patients do not seem to have PVC frequency linked to any discernable circadian distribution 24 
or HR changes. 25 
  26 
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We hypothesized that PVC circadian variation could help predict: 1) which patients may have 1 
infrequent intra-procedural PVCs, and 2) the likelihood of drug (i.e. isoproterenol) response 2 
when used to increase PVC frequency to allow activation mapping. In addition, we sought to 3 
describe patients’ clinical characteristics associated with each PVC profile, to assess possible 4 
mechanistic and clinical implications. 5 
 6 
 7 
METHODS   8 
Patient Characteristics 9 
Retrospective data collection was approved by the local institutional review boards at five 10 
international centers. Between December 2013 and May 2016, 101 consecutive patients with 11 
detailed 24-hour Holter monitoring and frequent idiopathic monomorphic PVCs referred for RFA 12 
were included in this study. Patients with cardiomyopathy were excluded if the PVCs were 13 
thought to be secondary to the underlying cardiomyopathy (i.e. scar-related). Cases of 14 
cardiomyopathy due to a high burden of PVCs were included as long as alternative etiologies of 15 
cardiomyopathy such as severe obstructive coronary artery or significant valvular disease were 16 
ruled out. 17 
 18 
Patient classification based on Holter PVC circadian distribution 19 
Patients were divided into 3 groups based on their hourly PVC relationship to the corresponding 20 
mean HR during the pre-procedure Holter monitoring (Figure 1). When their hourly PVC number 21 
had a positive correlation with the mean HR (Pearson, p<0.05), they were defined as fast HR-22 
dependent PVC (F-HR-PVC) type. Those with a negative correlation were defined as slow HR 23 
dependent PVC (S-HR-PVC) type. Finally, when there was no statistical link between PVC 24 
number and mean HR, they were defined as independent HR PVC (I-HR-PVC).  25 
 26 
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Ablation procedure 1 
Antiarrhythmic drugs other than amiodarone were discontinued at least five half-lives prior to 2 
ablation while amiodarone was usually stopped approximately 6 weeks prior as per institutional 3 
protocols. Intravenous sedation was minimized as tolerated to avoid anesthesia-related PVC 4 
suppression. Isoproterenol infusion was used as needed to induce PVCs when judged by the 5 
operator to be too infrequent for activation mapping, often after attempting burst pacing 6 
induction as well as decrease in intravenous sedation as tolerated. Mapping of the PVC origin 7 
was performed targeting the earliest site of activation compared with the onset of the surface 8 
PVC QRS complex, after which RFA was attempted using standard or irrigated radiofrequency 9 
energy after excluding proximity to a major coronary artery or the conduction system. In most 10 
cases, ablation was facilitated by use of a 3-dimentional electroanatomic mapping systems, with 11 
CARTO (Biosense-Webster, Diamond Bar, CA) or NavX (St. Jude Medical, Minneapolis, MN).  12 
Acute procedural success was defined as the absence of spontaneous or inducible clinical 13 
PVCs after an at least 30-minute waiting period following the successful RF application, either at 14 
baseline or after isoproterenol infusion if required to induce PVCs prior to ablation. 15 
 16 
Baseline evaluation and follow-up 17 
The most recent detailed baseline Holter monitoring including hourly PVC count and mean HR 18 
was analyzed. Transthoracic echocardiography was also performed prior to ablation to assess 19 
left ventricular ejection fraction (LVEF), quantified by using the Simpson’s biplane formula in 20 
sinus rhythm after at least 3 consecutive sinus beats. 21 
 22 
At least 1 post-ablation Holter monitor was obtained at each institution to document 23 
intermediate-long-term success; and echocardiography was commonly repeated once or twice a 24 
year for patients with initial impaired LVEF, until normalization or stabilization. Long-term 25 
ablation success was defined by a >80% decrease in Holter PVC burden associated with a 26 
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symptom improvement, at 3 months or later when available.9 As previously described, a PVC-1 
induced cardiomyopathy (PVC-CMP) was defined as an LVEF<50% that normalized after 2 
successful RFA.10 3 
 4 
Data collection 5 
Surface electrocardiograms (ECGs) from the diagnostic electrophysiological study were 6 
analyzed using electronic calipers at a 100 mm/s sweep speed. Only the clinical PVC was 7 
studied.  At baseline, PVC count per minute was averaged over 5 minutes prior to catheter 8 
insertion. Other measurements included the PVC coupling (averaged 6 consecutive PVCs when 9 
possible) the coupling variability (max-min) and the sinus beat RR and QT intervals.  10 
 11 
Infrequent intra-procedural PVCs was defined as a burden preventing adequate activation 12 
mapping (usually ≤1 or 2 PVC/min),6 requiring isoproterenol infusion. When isoproterenol was 13 
used, the same parameters were collected at the peak response. If isoproterenol could not 14 
increase PVC frequency, we again analyzed the same parameters during the washout period, 15 
which was defined as the time period when HR was decreasing, between isoproterenol 16 
cessation until return to baseline conditions. Finally, in one center (UCLA), when PVCs were not 17 
sustainably present at baseline or during isoproterenol infusion/washout, phenylephrine 18 
(repeated boluses) was used in order to obtain a 25% increase in systolic blood pressure (~30 19 
mmHg) triggering a vagal response decreasing HR (~10%). Again, PVC frequency, coupling, 20 
RR and QT intervals were measured during maximal drug effect. A significant response to drug 21 
was defined an increase in PVC frequency allowing comfortable mapping (≥5 PVCs/min). 22 
 23 
Statistical analysis  24 
Normally distributed variables were expressed as mean ± SD and compared, using Student’s t-25 
test or Mann-Whitney’s U-test, as appropriate. Categorical variables were expressed as counts 26 
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and percentages and were compared using the Chi-square test or Fisher’s exact test as 1 
appropriate. Receiver operating characteristic curves (ROC) were constructed to determine the 2 
cut-off value, sensitivity, and specificity of variables associated with infrequent intra-procedural 3 
PVCs. The area under the curve (AUC) was measured to discriminate the power of each 4 
parameter. To test whether there was a linear correlation between the 24-hour-holter hourly 5 
mean HR and their corresponding PVC frequencies, the Pearson correlation test was used to 6 
assess the strength of this relationship and classify patients into the F-HR-PVC, the S-HR-PVC 7 
or the I-HR-PVC groups given a positive (p<0.05), a negative (p<0.05) or no correlation (P=NS) 8 
was found, respectively. PVC count/min at baseline versus during drug infusions were 9 
compared using the paired t-test or Wilcoxon test as appropriate. ANOVA model was used to 10 
compare patient’s characteristics between the 3 subgroups.  A P<0.05 was considered 11 
statistically significant. Analyses were performed on SPSSv16.0 (SPSS Inc., Chicago, IL). 12 
 13 
 14 
RESULTS 15 
One hundred and one consecutive patients were included in this study. Clinical characteristics 16 
are summarized in table 1. Most patients referred for ablation were symptomatic (87.1%), with 17 
decreased LVEF (<50%) in 21.8% of cases. According to baseline Holter monitoring, the most 18 
common circadian PVC profile was a F-HR-PVC type, found in half (50.5%) of our patients 19 
(r=0.68±0.17), followed by I-HR-PVC (39.6%, r=0.09±0.21) and S-HR-PVC (9.9%, r=-0.56±0.15) 20 
profiles. Pharmacologic therapy had been prescribed prior to the index ablation in 75.2%, mainly 21 
beta-blockers (66.3%) and 28.7% had had at least 1 previous ablation attempt before the index 22 
procedure, and this subgroup had similar baseline characteristics. Right (43.6%) and Left 23 
(17.8%) outflow tracts were the most common PVC origins (Table 1). We could not identify a 24 
significant relationship between the different circadian PVC profiles and the PVC origin. 25 
 26 
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Predictors of infrequent intra-procedural PVCs 1 
Almost a third (30.7%) of our patient population had infrequent intra-procedural clinical PVC 2 
requiring drug infusion for activation mapping. These patients had a dramatically lower PVC 3 
count at the beginning of EPS compared to those who did not require drug infusion (1.1±1.9 4 
PVC/min vs 16.4±9.7 PVC/min; P<0.0001). It is noteworthy that they also had a significantly 5 
lower baseline HR during EPS (68.4±12.9 vs 77.7±13.1, P=0.001), despite the fact that the 6 
mean HR was similar between the two groups on their Holter recordings (74.3±11.3 vs 7 
74.8±11.3, P=0.953) and they had similar anesthesia protocols utilized.   8 
 9 
Approximately one third of patients with infrequent intra-procedural PVCs were present in each 10 
PVC profile group (31.4% of F-HR-PVC, 30% of I-HR-PVC and 30% of S-HR-PVC types; 11 
P=0.989). The best predictor of infrequent intra-procedural PVC was the number of hours with a 12 
PVC count<120/h (AUC=0.80, P<0.0001, sensitivity [Se]=83.9%, specificity [Spe]=74.3% for a 13 
cutoff ≥2 hours) on Holter monitoring. The overall PVC burden (%) was the second most 14 
powerful, but the most specific predictor (AUC=0.77, P<0.0001, Se=67.7% and Spe=75.7% for 15 
a cutoff ≤11.7%; Table 2). 16 
 17 
Impact of PVC circadian profile on intra-procedural drug response 18 
Among patient with infrequent intra-procedural PVC (n=31), 58.1% had a favorable response to 19 
at least 1 drug (Table 3). Patients responding to isoproterenol (48.4%, Figure 2) all had a F-HR-20 
PVC profile (r range [0.395 to 0.845], p<0.05) and isoproterenol was successful in all but 1 21 
patient, belonging to this group, who had polymorphic non-clinical PVCs induced. It is 22 
noteworthy that the magnitude of the PVC frequency response on isoproterenol in this group 23 
was not associated to the strength of the correlation coefficient (r) (p=0.489), nor it was to the 24 
intensity of the HR increase (p=0.545). Isoproterenol washout or phenylephrine was successful 25 
for the 3 patients with a S-HR-PVC type (r[-0.350 to -0.480], p<0.05); no drug could increase 26 
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PVC frequency in the 12 patients with an I-HR-PVC profile (r[-0.315 to 0.359], p=NS). It is 1 
noteworthy that the minimum cycle length at the peak response of isoproterenol was similar in 2 
patients responding and those who did not (545±112 versus 486±66 milliseconds; p=0.153). 3 
Examples of successful drug responses to isoproterenol and phenylephrine are shown in Figure 4 
3. 5 
 6 
PVC ablation outcome and impact of PVC frequency during EP study 7 
After a mean follow-up of 9±7 months, ablation success was achieved in 73.3% patients, the 8 
mean PVC burden in this group was 0.4±1.4% and none of them remained symptomatic. 9 
Intensification of medical therapy after failed ablation resulted in a significant PVC suppression 10 
in 4 additional patients; therefore, overall clinical success in our patient cohort was 77.2%. The 11 
highest ablation success rate (82.9%) was obtained for patients with frequent PVCs at baseline 12 
(Figure 4). Importantly, ablation success was not significantly different in the group of patients 13 
with infrequent PVC at baseline who responded to a drug (77.8%, P=0.732), but dramatically 14 
lower in those who did not respond to any drug (15.4%, P<0.0001). Therefore, PVC frequency 15 
during EPS (spontaneous or on drug) was an important determinant of ablation success 16 
(AUC=0.82, P<0.0001, Se=83.8%, Spe=74.1% for a cutoff of >7 PVC/min). Lastly, PVC origin 17 
was also associated with procedural outcome, with mitral annulus, para-hisian, papillary 18 
muscles, and epicardial foci displaying the poorest outcome. A PVC-CMP could be diagnosed 19 
with confidence (successful ablation with mean LVEF recovering from 35±9% to 53±8%) in 13 20 
(12.9%) patients; 6 (11.8%) from the F-HR-PVC, 6 (15%) from the I-HR-PVC and 1 (10%) from 21 
the S-HR-PVC group (P=0.868). 22 
 23 
 24 
DISCUSSION 25 
Main findings 26 
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This is the first study assessing the impact of PVC circadian variation on procedural outcome, 1 
including drug responses. Our main findings are: 2 
1) There are 3 distinct PVC profiles based on the correlation of hourly PVC frequency 3 
distribution to HR changes and a significant positive correlation (F-HR-PVC) 4 
characterized 50% of cases. 5 
2) Infrequent intra-procedural PVCs affected about one third of patients and may reduce 6 
ablation success. PVC burden (≤11.7%) as well as at least 2 hours with less than 120 7 
PVCs on a 24-hour ECG-Holter, best predicted patients where ablation was likely to be 8 
unsuccessful. 9 
3) Infrequent intra-procedural F-HR-PVC types likely responded to isoproterenol, S-HR-10 
PVC types to washout or phenylephrine, while no drug could increase PVCs in the I-HR-11 
PVC type. 12 
4) Finally, patients with drug response had the similar intermediate-term ablation success 13 
rates to patients with frequent PVC at baseline, while patients in whom drugs failed to 14 
increase PVCs (i.e. infrequent I-HR-PVC type) displayed a poor outcome. 15 
 16 
PVC ablation has been used to manage drug-refractory symptoms and has become the 17 
preferred approach to treat and prevent PVC-induced cardiomyopathy.5 Long-term PVC 18 
suppression is essential for total and durable recovery because a delayed recurrence of 19 
frequent PVCs has been reported to result in recurrence of PVC-induced cardiomyopathy.11 A 20 
classically described cause of RFA failure is the inability to reach the site of origin for technical 21 
or anatomical reasons. However, another important cause, independent of the PVC location, is 22 
when there is insufficient intra-procedural PVCs for mapping.6 When there are insufficient PVCs 23 
to map this leads to the inability to precisely identify the site of origin.  Some operators then 24 
utilize pace mapping as surrogate, which has poor spatial resolution, and lacks a reliable 25 
procedural endpoint.  26 
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 1 
Baser and colleagues reported that patients with a PVC count <32 during the first 30 min of 2 
procedure had lower success rates at 3 months. Similarly, they found that approximately one 3 
third of their patients were affected by low burden at baseline and that most of those patients 4 
(59%) did not respond to isoproterenol.6  The current study provides data that will help predict 5 
which patients are at risk of infrequent intra-procedural PVCs, and more importantly, in which 6 
cases an increase in PVC frequency can be expected in response respond to drug (and to 7 
which drugs). In our study, patients who had a pharmacological response, compared to those 8 
who did not, had a better clinical outcome (Figure 4). 9 
 10 
Autonomic involvement in arrhythmogenesis is well established.12 We report in this study 11 
distinct circadian PVC profiles. The I-HR-PVC suggests a pathogenesis likely independent from 12 
autonomic variation, while the F-HR-PVC type is evoked by adrenergic triggers and the S-HR-13 
PVC evoked by vagal triggers. Increased sympathetic and parasympathetic activity estimated 14 
through heart rate variability parameters has been specifically described during the onset of 15 
PVCs displaying these respective profiles.13 The fact that patients with F-HR-PVC responded 16 
with increased PVC frequency to isoproterenol, a beta2-receptor agonist, which has been used 17 
for decades to reproduce sympathetically-mediated arrhythmias, further supports this concept.  18 
 19 
Phenylephrine, an α-adrenergic agonist, induces a vagal baroreflex activation, mediated 20 
through acute rise in blood pressure following vasoconstriction.14 Attempts to induce 21 
arrhythmias with this drug in Brugada syndrome patients has been made in the past, because 22 
these patients are at risk of sudden cardiac death specifically at rest.15 Because only 3 patients 23 
in the S-HR-PVC type needed drug infusion and phenylephrine was used in only one center, we 24 
report in this study only one attempt. Nonetheless we believe it is a promising patient-25 
customized approach to increase PVC frequency during mapping in this subgroup that should 26 
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be evaluated further. This specific patient had a mild (6/min) and temporary (≤1 min) increase of 1 
PVC during isoproterenol washout that was more intense and more sustained with 2 
phenylephrine infusion (12/min until RF delivery). Isoproterenol washout corresponds to a more 3 
complex situation mimicking exercise recovery during which, while sympathetic drive is 4 
decreasing, parasympathetic drive is progressively increasing in healthy subjects.16 Therefore, 5 
the suitable autonomic balance targeted to increase PVC frequency in the S-HR-PVC group 6 
may be achieved only for a brief period. Nonetheless, we could successfully use this technique 7 
for the 2 other patients requiring drug challenge is this subgroup.  8 
 9 
There are several possible mechanistic explanations for how increased vagal tone could 10 
increase PVC frequency. In the setting of a normally automatic focus surrounded by a region of 11 
depressed excitability (i.e. allowing entrance block but not always exit block), a slower sinus rate 12 
may result in appearance of PVC without any change in the underlying substrate (modulated 13 
parasystole). Furthermore, increased vagal activity has been shown to prolong ventricular action 14 
potential duration 17 and also transiently elicit inexcitable zones near an ectopic pacemaker in 15 
atrial tissue. Thus, it may protect it from conducted sinus impulses and, in the setting of slow 16 
heart rate, it may result in spontaneous discharges likely manifest as late coupled PVCs.18  17 
 18 
It this study, no differences in the mean CI, the CI variability or the PVC location between 19 
subgroups was found that could have helped decipher the plausible pathophysiology linked to 20 
each subtype (Table 4). It is also noteworthy that although recent studies shed light on some of 21 
the pathophysiologic aspects and consequences of the coupling interval and its variability, it 22 
remains a complex interaction, not yet fully elucidated.3, 19 Nonetheless, similar to vagally 23 
mediated atrial fibrillation, patients in the S-HR-PVC subgroup were significantly younger; 24 
therefore, increased normal automaticity (of a focus), is a likely plausible mechanism (unlike 25 
reentry or afterdepolarizations) in this subgroup of “healthier” patients. 26 
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 1 
Clinical Implications 2 
This study, based on a detailed analysis of the PVC circadian variation on Holter monitoring 3 
allowing a classification in 3 distinct subgroups, provides a simple clinical tool that may guide 4 
ablation management in patients with frequent PVCs. Further, it may help inform patients with a 5 
more realistic and customized outcome estimation.  6 
 7 
Mapping in F-HR-PVC (r≥0.4) patients with a high likelihood of infrequent intra-procedural PVCs 8 
should be managed with isoproterenol use. Likewise, for slow-HR-PVC (r≤-0.35), phenylephrine 9 
may be useful, but further data are needed. However, I-HR-PVC patients with infrequent 10 
intraprocedural PVCs have a low likelihood of success, as our data demonstrates that no 11 
commonly used drug can induce PVCs in these cases. Therefore, when patients are known to 12 
have I-HR-PVCs, we believe PVC frequency should be monitored before entering the EP lab 13 
and the procedure potentially rescheduled when PVC burden is not sufficient at the time. In 14 
addition, we believe that this data can be made easily accessible to clinicians by having Holter 15 
software automatically generate the PVC/HR correlation coefficient and display it on reports. 16 
 17 
An additional point can me made regarding procedural cost. In many centers after ablation of 18 
the targeted PVC, isoproterenol is used to test whether PVCs can be re-induced regardless of 19 
whether the drug was needed to allow for mapping. Knowing isoproterenol is effective in less 20 
than 50% of cases and, only in the F-HR-PVC subgroup, it should not be used post-ablation, 21 
except in these specific cases. Knowing when isoproterenol can be useful ahead of time has the 22 
potential to save both time and procedural cost. 23 
 24 
Limitations 25 
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This is a retrospective study. Since isoproterenol always increased PVC frequency in the setting 1 
of infrequent F-HR-PVC, phenylephrine was not tested in the subgroup. Different drug 2 
administration approaches (bolus vs continuous infusions, maximal dose, etc.) were used in the 3 
different centers in this study; nonetheless infusion protocol did not seem to interfere with drug 4 
responses and this is likely to increase the applicability of our results to centers using different 5 
ablation protocols to manage PVCs. Predictors of infrequent intra-procedural PVCs as well as 6 
our circadian variation PVC classification were based a single Holter monitor prior to the 7 
ablation procedure; yet inter-Holter PVC burden variability has been described in patients with 8 
repeated Holters. More specifically, whether the correlation between PVC frequency and HR 9 
could vary between different Holter monitoring sessions and whether a patient could have 10 
several PVCs displaying different circadian profiles remains unclear and should be the focus of 11 
further research. Our classification that has been developed based on Pearson correlation to 12 
identify a linear correlation between the hourly mean HR and PVC frequency may not identify 13 
unusual association such as PVC frequency concentrated during a very narrow range of HR or 14 
specific moments of the day, and therefore classify them as I-HR-PVC. It is noteworthy that 15 
PVCs were not excluded from the mean HR count that is automatically generated by Holter 16 
software. Nonetheless, interpolated PVCs were not common and therefore PVC presence did 17 
not affect the mean HR calculation. 18 
 19 
Conclusion: A simple analysis of Holter PVC circadian variability may provide incremental 20 
value to predict infrequent intra-procedural PVCs, guide pharmacologic induction of PVCs 21 
during RFA, and predict outcome. Patients with infrequent Fast or Slow HR-PVCs have a high 22 
likelihood of successful ablation when PVC frequency can be pharmacologically enhanced, 23 
while those with infrequent I-HR-PVC have a low ablation success rate regardless of 24 
intervention when infrequent baseline PVCs are present. 25 
 26 
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Table 1 Baseline characteristics 4 
 All 
(n=101) 
 Age, yrs 
 Male 
 LVEF, % 
 Symptoms 
    Palpitations 
    Dyspnea 
 Sustained ventricular tachycardia 
 Syncope 
 Non-sustained ventricular tachycardia 
 PVC burden, % 
 SDNN, ms 
 SDANN 
 Fast-HR-PVC 
 Independent-HR-PVC 
 Slow-HR-PVC 
 Drug prior ablation 
    Beta-blocker 
    CCB 
    Class I AAD 
    Amiodarone 
    Other 
PVC origin: 
   RVOT 
   Para-Hisian/intra-septal 
   Tricuspid annulus 
   Other RV Endo 
   LVOT 
   Mitral annular 
   Papillary muscle 
49.9±16.9 
57(56.4) 
55.5±12.1 
88(87.1) 
76(75.2) 
23(22.8) 
1(1.0) 
3(2.9) 
8(7.9) 
19.7±12.3 
145.2±51.6 
113.2±38.4 
51(50.5) 
40(39.6) 
10(9.9) 
76(75.2) 
67(66.3) 
12(11.9 
17(16.8) 
5(4.9) 
5(4.9) 
 
44(43.6) 
9(8.9) 
2(2.0) 
4(4.0) 
18(17.8) 
7(6.9) 
2(2.0) 
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   Other LV endo 
   Epicardial 
   Unknown 
6(5.9) 
7(6.9) 
2(2.0) 
  
 1 
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Table 2: Predictors of infrequent intra-procedural PVC during EP study requiring drug trial 
 
 Patients with 
Infrequent Intra-
procedural PVC 
(n=31) 
Patients 
Without 
Infrequent 
intra-
procedural 
PVC 
(n=70) 
 
 
P 
 
 
AUC 
 
 
Cutoff 
 
 
Se 
 
 
Spe 
Holter-PVC burden (%) 
Holter-lowest hourly PVC count (n/h) 
Holter-hours (n) with PVC <120/h 
EPS baseline mean heart-rate 
12.2±10.1 
120±342 
7.4±7.1 
68.4±12.9 
23.0±11.8 
362±462 
1.8±3.3 
77.7±13.1 
<0.001 
<0.001 
<0.001 
0.001 
0.77 
0.74 
0.80 
0.69 
≤11.7 
≤88 
≥2 
≤78 
67.7 
82.8 
83.9 
86.7 
75.7 
65.2 
74.3 
49.3 
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Table 3 Response to different drugs during EPS in patients with infrequent intra-procedural PVC at baseline. 
 
Patients needing 
Drug infusion 
Isoproterenol 
infusion 
Isoproterenol 
washout 
Phenylephrine 
infusion 
Epinephrine 
infusion 
All n (% success) 
Fast-HR-PVC 
Indep-HR-PVC 
Slow-HR-PVC 
15/31(48.4) 
15/16(93.7) 
0/12(0) 
0/3(0) 
3/16(18.7) 
0/1(0) 
0/12(0) 
3/3(100) 
1/9(11.1) 
0/1(0) 
0/7 
1/1(100%) 
0/6(0) 
Ø 
0/6(0) 
Ø 
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Table 4: Patients/PVC characteristics in the 3 subgroups 
 
 
 
N(%) 
Fast-HR 
PVC 
 
51(50.5) 
Indep-HR 
PVC 
 
40(39.6) 
Slow-HR 
PVC 
 
10(9.9) 
p 
Age 
Male 
PVC burden, % 
LVEF, % 
PVC/min at baseline 
Mean Coupling 
Coupling variability (max-min) 
PVC localization 
   RVOT 
   Para-Hisian/intra-septal 
   Tricuspid annulus 
   Other RV Endo 
   LVOT 
   Mitral annular 
   Papillary muscle 
   Other LV endo 
   Epicardial 
   Unknown 
52.7±17.4 
28(54.9) 
20.4±13.2 
55.2±12.3 
10.5±10.8 
485.3±69.3 
63.0±70.9 
 
21(41.2) 
4(7.8) 
1(2.0) 
3(5.9) 
9(17.6) 
2(3.9) 
1(2.0) 
6(11.8) 
4(7.8) 
0(0) 
50.1±14.9 
24(60) 
19.3±11.6 
55.7±12.2 
12.1±10.5 
478.4±70.7 
63.3±43.8 
 
17(42.5) 
4(10.0) 
1(2.5) 
1(2.5) 
8(20.0) 
1(2.5) 
1(2.5) 
2(5.0) 
3(7.5) 
2(5.0) 
34.3±12.8 
5(50) 
18.0±11.0 
56.5±7.3 
13.5±12.5 
463.4±83.8 
36.4±42.0 
 
6(60) 
0(0) 
0(0) 
1(10) 
1(10) 
0(0) 
0(0) 
2(20.0) 
0(0) 
0(0) 
0.006 
0.848 
0.820 
0.946 
0.484 
0.669 
0.451 
NS 
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Figure 1: Holter example of the 3 PVC circadian profiles 
 
The left panels, generated by holter software, represent mean heart rate (top) and PVC 
count/hour (bottom) over the 24 hours. The right panels represent the PVC count (y) over the 
mean heart rate (x) distribution (correlation) derived from holter hourly summary raw data. 
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Figure 2: Isoproterenol response in patients with infrequent intraprocedural 
PVC 
 
 
 
Representation of the PVC frequency (PVC/min) during the electrophysiological study at 
baseline and during isoproterenol infusion in all and subgroups of patients with infrequent intra-
procedural PVC. Each line represents a different patient. 
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Figure 3: Example of drug response to isoproterenol for F-HR-PVC and to 
phenylephrine for S-HR-PVC 
 
 
  
The first patient (F-HR-PVC) had no PVC spontaneously present at baseline while the PVC 
frequency dramatically increased during isoproterenol infusion allowing mapping. Likewise, the 
second patient (S-HR-PVC) had very infrequent PVCs at baseline but also during isoproterenol 
infusion and phenylephrine could successfully increase its frequency. Therefore, the 2 patients 
had successful ablations.  
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Figure 4: Impact of PVC frequency during EP study on ablation outcome 
 
 
*** p<0.0001 
